Glepaglutide for short bowel syndrome
Glepaglutide is being developed as a GLP-2 analog for the treatment of Short Bowel Syndrome (SBS). SBS patients cannot absorb enough nutrients and fluids through the gastrointestinal tract.
Short bowel syndrome is a severe condition with significant therapeutic needs
Short bowel syndrome (SBS) is a life-threatening and complex chronic severe condition associated with reduced or complete loss of intestinal function. The main underlying causes of SBS are major intestinal surgery following Crohn’s disease, ischemia, radiation damage and surgery in adults. In young children, congenital intestinal atresia, necrotizing enteric colitis and intestinal volvulus are the most common causes. In older children and adolescents, SBS is mainly due to volvulus or trauma.
It is estimated that 20,000-40,000 patients are affected by SBS in the U.S. and Europe. The most severely affected people are dependent on daily parenteral support. This requires them to be connected to infusion lines and pumps, which pose significant restrictions on a patient’s ability to engage in daily activities.
Glepaglutide is a long-acting GLP-2 analog
If people are diagnosed with SBS and also has intestinal failure (IF) then the person is dependent on total parenteral nutrition also called home parenteral nutrition (TPN or HPN). That means that the small intestine cannot absorb nutrition nor fluids and will need to be delivered via bags of nutrition and fluids via a central venous catheter also known as a central line catheter. If the patient does not have intestinal failure (IF) but is considered intestinal insufficient (also called II) - those patients are not dependent on getting their nutrients via a central catheter. Those II patients may become at risk of becoming an IF patient - if the condition worsens.